Please enable JavaScript to continue using this application.

Compare $LCTX vs $MGNX | Chartloom

Compare

$LCTX vs $MGNX

Lineage Cell Therapeutics Inc · MacroGenics Inc

LCTX

Lineage Cell Therapeutics Inc

MGNX

MacroGenics Inc

Compare $LCTX vs $MGNX

Comparing Lineage Cell Therapeutics Inc and MacroGenics Inc

LCTXLineage Cell Therapeutics Inc

MGNXMacroGenics Inc

LCTXLineage Cell Therapeutics Inc

Market cap

$248M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

28.49x

Rev growth (TTM)

-37.1%

YTD performance

-39.4%

52W performance

-42.5%

FCF yield

-10.0%

MGNXMacroGenics Inc

Market cap

$238M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

2.39x

Rev growth (TTM)

1.3%

YTD performance

132.3%

52W performance

110.1%

FCF yield

-27.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

LCTX

MGNX

Detailed metrics comparison

LCTX

Lineage Cell Therapeutics Inc

MGNX

MacroGenics Inc

Market Cap

LCTX$248M

MGNX$238M

Enterprise Value

LCTX$210M

MGNX$302M

Price

LCTX$0.99

MGNX$3.74

P/E Ratio

LCTXN/A

MGNXN/A

P/S Ratio

LCTX18.94x

MGNX1.42x

EV/Sales

LCTX16.09x

MGNX1.80x

EV/EBITDA

LCTX0.00x

MGNX5.31x

P/B Ratio

LCTX3.86x

MGNX5.32x

P/FCF Ratio

LCTXN/A

MGNXN/A

EV/FCF

LCTX-8.48x

MGNX-4.61x

PEG Ratio

LCTXN/A

MGNXN/A

Forward P/E (NTM)

LCTXN/A

MGNXN/A

Forward P/S (NTM)

LCTX28.49x

MGNX2.39x

Revenue (TTM)

LCTX$13M

MGNX$168M

Revenue Growth (YoY)

LCTX-37.1%

MGNX1.3%

Forward Rev Growth

LCTX-16.6%

MGNX-12.8%

Gross Margin (TTM)

LCTX94.1%

MGNX61.8%

Operating Margin (TTM)

LCTX0.0%

MGNX0.0%

EBITDA Margin (TTM)

LCTX-199.6%

MGNX-20.8%

Net Margin (TTM)

LCTX-246.6%

MGNX-8.7%

FCF Margin (TTM)

LCTX-189.7%

MGNX-39.1%

Net Income (TTM)

LCTX$-32M

MGNX$-15M

FCF (TTM)

LCTX$-25M

MGNX$-66M

EPS (TTM)

LCTX-$0.13

MGNX-$0.23

ROE (TTM)

LCTX-7114.0%

MGNX-3127.0%

ROA (TTM)

LCTX-3087.0%

MGNX-535.0%

ROIC (TTM)

LCTX-7104.0%

MGNX-1017.0%

Cash

LCTX$37M

MGNX$114M

Debt

LCTX$48K

MGNX$178M

Net Cash/Debt

LCTX$37M

MGNX$-64M

Current Ratio (TTM)

LCTX6.61x

MGNX2.96x

Quick Ratio (TTM)

LCTX6.44x

MGNX2.92x

Debt/Equity (TTM)

LCTX0.00x

MGNX4.16x

Debt/Assets (TTM)

LCTX0.0%

MGNX0.0%

Interest Coverage (TTM)

LCTXN/A

MGNXN/A

Net Debt/EBITDA (TTM)

LCTX0.00x

MGNX0.00x

Beta

LCTX1.67

MGNX1.25

52W Performance

LCTX-42.5%

MGNX110.1%

YTD Performance

LCTX-39.4%

MGNX132.3%

% from 52W High

LCTX-52.4%

MGNX-26.4%

% from 52W Low

LCTX12.7%

MGNX189.9%

Asset Turnover (TTM)

LCTX0.07x

MGNX0.61x

FCF Yield (TTM)

LCTX-10.0%

MGNX-27.6%

Earnings Yield (TTM)

LCTX-13.0%

MGNX-6.1%

Dividend Yield (TTM)

LCTXN/A

MGNXN/A

Rule of 40

LCTX-226.8

MGNX-37.8

EV/GP/RG

LCTXN/A

MGNXN/A

Ticker research

View LCTX research View MGNX research

Metric	LCTX Lineage Cell Therapeutics Inc	MGNX MacroGenics Inc
Market & Valuation
Market Cap	$248M	$238M
Enterprise Value	$210M	$302M
Price	$0.99	$3.74
P/E Ratio	N/A	N/A
P/S Ratio	18.94x	1.42x
EV/Sales	16.09x	1.80x
EV/EBITDA	0.00x	5.31x
P/B Ratio	3.86x	5.32x
P/FCF Ratio	N/A	N/A
EV/FCF	-8.48x	-4.61x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	28.49x	2.39x
Revenue & Growth
Revenue (TTM)	$13M	$168M
Revenue Growth (YoY)	-37.1%	1.3%
Forward Rev Growth	-16.6%	-12.8%
Profitability
Gross Margin (TTM)	94.1%	61.8%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-199.6%	-20.8%
Net Margin (TTM)	-246.6%	-8.7%
FCF Margin (TTM)	-189.7%	-39.1%
Net Income (TTM)	$-32M	$-15M
FCF (TTM)	$-25M	$-66M
EPS (TTM)	-$0.13	-$0.23
ROE (TTM)	-7114.0%	-3127.0%
ROA (TTM)	-3087.0%	-535.0%
ROIC (TTM)	-7104.0%	-1017.0%
Financial Health
Cash	$37M	$114M
Debt	$48K	$178M
Net Cash/Debt	$37M	$-64M
Current Ratio (TTM)	6.61x	2.96x
Quick Ratio (TTM)	6.44x	2.92x
Debt/Equity (TTM)	0.00x	4.16x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.67	1.25
52W Performance	-42.5%	110.1%
YTD Performance	-39.4%	132.3%
% from 52W High	-52.4%	-26.4%
% from 52W Low	12.7%	189.9%
Efficiency & Yields
Asset Turnover (TTM)	0.07x	0.61x
FCF Yield (TTM)	-10.0%	-27.6%
Earnings Yield (TTM)	-13.0%	-6.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-226.8	-37.8
EV/GP/RG	N/A	N/A
Ticker research	View LCTX research	View MGNX research

Valuation

P/S Ratio

MGNX

1.42x

LCTX

18.94x

EV/FCF

LCTX

-8.48x

MGNX

-4.61x

Growth & revenue

Revenue Growth TTM

MGNX

1.3%

LCTX

-37.1%

Forward Revenue Growth

MGNX

-12.8%

LCTX

-16.6%

Profitability & performance

Gross Margin

LCTX

94.1%

MGNX

61.8%

ROE

MGNX

-3127.0%

LCTX

-7114.0%

FCF Yield %

LCTX

-10.0%

MGNX

-27.6%

52-Week Performance

MGNX

110.1%

LCTX

-42.5%

Detailed metrics comparison

LCTX

Lineage Cell Therapeutics Inc

MGNX

MacroGenics Inc

Market Cap

LCTX$248M

MGNX$238M

Enterprise Value

LCTX$210M

MGNX$302M

Price

LCTX$0.99

MGNX$3.74

P/E Ratio

LCTXN/A

MGNXN/A

P/S Ratio

LCTX18.94x

MGNX1.42x

EV/Sales

LCTX16.09x

MGNX1.80x

EV/EBITDA

LCTX0.00x

MGNX5.31x

P/B Ratio

LCTX3.86x

MGNX5.32x

P/FCF Ratio

LCTXN/A

MGNXN/A

EV/FCF

LCTX-8.48x

MGNX-4.61x

PEG Ratio

LCTXN/A

MGNXN/A

Forward P/E (NTM)

LCTXN/A

MGNXN/A

Forward P/S (NTM)

LCTX28.49x

MGNX2.39x

Revenue (TTM)

LCTX$13M

MGNX$168M

Revenue Growth (YoY)

LCTX-37.1%

MGNX1.3%

Forward Rev Growth

LCTX-16.6%

MGNX-12.8%

Gross Margin (TTM)

LCTX94.1%

MGNX61.8%

Operating Margin (TTM)

LCTX0.0%

MGNX0.0%

EBITDA Margin (TTM)

LCTX-199.6%

MGNX-20.8%

Net Margin (TTM)

LCTX-246.6%

MGNX-8.7%

FCF Margin (TTM)

LCTX-189.7%

MGNX-39.1%

Net Income (TTM)

LCTX$-32M

MGNX$-15M

FCF (TTM)

LCTX$-25M

MGNX$-66M

EPS (TTM)

LCTX-$0.13

MGNX-$0.23

ROE (TTM)

LCTX-7114.0%

MGNX-3127.0%

ROA (TTM)

LCTX-3087.0%

MGNX-535.0%

ROIC (TTM)

LCTX-7104.0%

MGNX-1017.0%

Cash

LCTX$37M

MGNX$114M

Debt

LCTX$48K

MGNX$178M

Net Cash/Debt

LCTX$37M

MGNX$-64M

Current Ratio (TTM)

LCTX6.61x

MGNX2.96x

Quick Ratio (TTM)

LCTX6.44x

MGNX2.92x

Debt/Equity (TTM)

LCTX0.00x

MGNX4.16x

Debt/Assets (TTM)

LCTX0.0%

MGNX0.0%

Interest Coverage (TTM)

LCTXN/A

MGNXN/A

Net Debt/EBITDA (TTM)

LCTX0.00x

MGNX0.00x

Beta

LCTX1.67

MGNX1.25

52W Performance

LCTX-42.5%

MGNX110.1%

YTD Performance

LCTX-39.4%

MGNX132.3%

% from 52W High

LCTX-52.4%

MGNX-26.4%

% from 52W Low

LCTX12.7%

MGNX189.9%

Asset Turnover (TTM)

LCTX0.07x

MGNX0.61x

FCF Yield (TTM)

LCTX-10.0%

MGNX-27.6%

Earnings Yield (TTM)

LCTX-13.0%

MGNX-6.1%

Dividend Yield (TTM)

LCTXN/A

MGNXN/A

Rule of 40

LCTX-226.8

MGNX-37.8

EV/GP/RG

LCTXN/A

MGNXN/A

Ticker research

View LCTX research View MGNX research

Metric	LCTX Lineage Cell Therapeutics Inc	MGNX MacroGenics Inc
Market & Valuation
Market Cap	$248M	$238M
Enterprise Value	$210M	$302M
Price	$0.99	$3.74
P/E Ratio	N/A	N/A
P/S Ratio	18.94x	1.42x
EV/Sales	16.09x	1.80x
EV/EBITDA	0.00x	5.31x
P/B Ratio	3.86x	5.32x
P/FCF Ratio	N/A	N/A
EV/FCF	-8.48x	-4.61x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	28.49x	2.39x
Revenue & Growth
Revenue (TTM)	$13M	$168M
Revenue Growth (YoY)	-37.1%	1.3%
Forward Rev Growth	-16.6%	-12.8%
Profitability
Gross Margin (TTM)	94.1%	61.8%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-199.6%	-20.8%
Net Margin (TTM)	-246.6%	-8.7%
FCF Margin (TTM)	-189.7%	-39.1%
Net Income (TTM)	$-32M	$-15M
FCF (TTM)	$-25M	$-66M
EPS (TTM)	-$0.13	-$0.23
ROE (TTM)	-7114.0%	-3127.0%
ROA (TTM)	-3087.0%	-535.0%
ROIC (TTM)	-7104.0%	-1017.0%
Financial Health
Cash	$37M	$114M
Debt	$48K	$178M
Net Cash/Debt	$37M	$-64M
Current Ratio (TTM)	6.61x	2.96x
Quick Ratio (TTM)	6.44x	2.92x
Debt/Equity (TTM)	0.00x	4.16x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.67	1.25
52W Performance	-42.5%	110.1%
YTD Performance	-39.4%	132.3%
% from 52W High	-52.4%	-26.4%
% from 52W Low	12.7%	189.9%
Efficiency & Yields
Asset Turnover (TTM)	0.07x	0.61x
FCF Yield (TTM)	-10.0%	-27.6%
Earnings Yield (TTM)	-13.0%	-6.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-226.8	-37.8
EV/GP/RG	N/A	N/A
Ticker research	View LCTX research	View MGNX research